ReviewMolecular pharmacology2009
Mechanisms of pharmacogenomic effects of genetic variation within the cardiac adrenergic network in heart failure.
Review in Molecular pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Review
- Review
- Caveolins as Regulators of Stress Adaptation.Molecular pharmacology · 2018Review
- The influence of two functional genetic variants of GRK5 on tau phosphorylation and their association with Alzheimer's disease risk.Oncotarget · 2017Article
- βScientific reports · 2017Article
- Site-specificThe Journal of biological chemistry · 2017Article
- Factors affecting the development of adverse drug reactions to β-blockers in hospitalized cardiac patient population.Patient preference and adherence · 2016Article
- Etiology-specific assessment of predictors of long-term survival in chronic systolic heart failure.International journal of cardiology. Heart & vasculature · 2015Article
- Modeling the effects of β1-adrenergic receptor blockers and polymorphisms on cardiac myocyte Ca2+ handling.Molecular pharmacology · 2014Article
- Arg389Gly β1-adrenergic receptor polymorphism and susceptibility to syncope during tilt test.Archives of medical science : AMS · 2014Article
- S49G and R389G polymorphisms of the β₁-adrenergic receptor influence signaling via the cAMP-PKA and ERK pathways.Physiological genomics · 2013Article
- The role of G protein coupled receptor kinases in neurocardiovascular pathophysiology.Archives of medical science : AMS · 2012Article
- Article
- Genetic variation, β-blockers, and perioperative myocardial infarction.Anesthesiology · 2011Review
- Nuclear effects of G-protein receptor kinase 5 on histone deacetylase 5-regulated gene transcription in heart failure.Circulation. Heart failure · 2011Article
- Polymorphisms present in G-protein-coupled receptor kinases and their effect on β-blocker treatment.Pharmacogenomics · 2011Article
- Akt2 deficiency promotes cardiac induction of Rab4a and myocardial β-adrenergic hypersensitivity.Journal of molecular and cellular cardiology · 2010Article
- Common ADRB2 haplotypes derived from 26 polymorphic sites direct beta2-adrenergic receptor expression and regulation phenotypes.PloS one · 2010Article
- Progress toward genetic tailoring of heart failure therapy.Current opinion in molecular therapeutics · 2010Review
- Role of β-blocker therapy in pediatric heart failure.Pediatric health · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
One of the goals of pharmacogenomics is the use of genetic variants to predict an individual's response to treatment. Although numerous candidate and genome-wide associations have been made for cardiovascular response-outcomes, little is known about how a given polymorphism imposes the phenotype. Such mechanisms are important, because they tie the observed human response to specific signaling alterations and thus provide cause-and-effect relationships, aid in the design of hypothesis-based clinical studies, can help to devise workaround drugs, and can reveal new aspects of the pathophysiology of the disease. Here we discuss polymorphisms within the adrenergic receptor network in the context of heart failure and beta-adrenergic receptor blocker therapy, where multiple approaches to understand the mechanism have been undertaken. We propose a comprehensive series of studies, ranging from transfected cells, transgenic mice, and ex vivo and in vitro human studies as a model approach to explore mechanisms of action of pharmacogenomic effects and extend the field beyond observational associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.